Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Danish leader will face a challenging landscape among competitors ...

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...